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In lieu of an abstract, below is the article's first paragraph.
In the past few years, a new area of genetics has emerged that has scientists in many other fields intrigued. The
discovery of telomeres, the end segments on our chromosomes, and the enzyme that controls them, has
evoked an interest in professionals from a wide range of specialties. Articles on the subject have appeared in
journals of cell and molecular biology, microbiology, genetics, gerontology, and have even surfaced in the
popular media. There is already a wealth of information to be found on the topic, yet there is many times more
still to be discovered, in several different fields. Because of the relatedness of this topic to so many areas,
telomere biology has almost emerged as a branch of biology in and of itself.
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The Telomere and Telomerase Activity 
by 
Kerrie Conwell 
In the past few years, a new area of genetics has emerged that has scientists in many 
other fields intrigued. The discovery oftelomeres, the end segments on our chromosomes, and 
the enzyme that controls them, has evoked an interest in professionals from a wide range of 
specialties. Articles on the subject have appeared in journals of cell and molecular biology, 
microbiology, genetics, gerontology, and have even surfaced in the popular media. There is 
already a wealth of information to be found on the topic, yet there is many times more still to 
be discovered, in several different fields. Because of the relatedness of this topic to so many 
areas, telomere biology has almost emerged as a branch of biology in and of itself 
The telomere is a segment of DNA that is comprised of several tandemly repeated, G-rich 
sequences of nucleotides located at the tip of virtually all eukaryotic chromosomes. In humans 
and in mice, the sequence is TT AGGG, and can be repeated as many as several thousand times. 
It is considered by some to be the "mitotic clock" (Counter, 1994) of the cell, controlling the 
number of times the cell can replicate before senescence, or cell aging, occurs: a gradual but 
steady decrease in cell viability (Lendway, et al., 1996). It also serves to enable the cell to 
differentiate between intact and broken chromosomes, and is involved in chromosomal 
separation. Although telomeres are present in a wide variety of species, from single-celled 
protozoa to vertebrates such as mice and humans, they exhibit a similarity in form and function 
among each of these. 
Normal DNA is a double-helical, or double-stranded spiral structure made up of 
nitrogenous base pairs of either adenine-thymine or cytosine-guanine. DNA replicates from the 
5' to the 3' end, according to the nucleotide sequence of the template, which is a preset 
"pattern". It is initiated at a certain spot on the chromosome, the origin of replication, and 
continues from there by DNA polymerase, a catalytic enzyme that can only begin replication 
along a previously existing template. The polymerase contains its own 8- 12 base pair stretch of 
RNA that acts as a primer, preparing the original chromosome for replication, after which the 
primer is removed. 
Restriction enzymes control expression and repression of genes, deleting and inserting 
those that are necessary or harmful. The DNA double helix is unwound by a protein called 
helicase, and also present are single-stranded binding proteins, which keep the DNA straight 
and prevent intrastrand hydrogen bonds. Since replication occurs simultaneously along both 
strands, in opposite directions, one strand can replicate continuously (the leading strand), and 
on the other (the Jagging strand) it occurs in fragments. But because of the removal of the 
primer, one end of the chromosome will be short 8-12 base pairs. If there were not a structure 
to protect the ends of the chromosomes, they would be gradually degraded, even in the 
absence of cell division (Zalcian, 1995). 
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The telomere replicates differently. The telomeric segment is added onto the 3' end of 
the linear DNA molecule by telomerase, a DNA polymerase specific for this function. This 
enzyme contains within itself a short RNA template, and therefore does not need the DNA 
template; it uses the RNA as a primer, and once replication is completed, the primer is 
removed. Telomerase is a reverse transcriptase, which means that instead of converting DNA 
to RNA and back to DNA, as other DNA polymerases do, it uses its own RNA to directly 
synthesize DNA from its template. The telomerase adds the new sequences onto the tip of the 
lagging strand of the chromosome, creating an "overhang" on one strand which forms a sort of 
"cap" to prevent DNA damage during each cell division. Telomerase also prevents gene 
rearrangements and further loss of genetic information by keeping the ends from fusing 
together during division, which would cause DNA damage and prevent replication. 
In vitro, the G-rich overhang of the telomere can bend over upon itself, and form 
special guanine-guanine base pairs, and sometimes four-stranded helices. These DNA 
structures are more stable than the single-stranded overhang (Zakian, 1995), which increases 
its ability to protect the end of the chromosome. The fact that the guanines are bound together 
prevents them from serving as a template for the production of more telomerase, and so not 
only does it shorten the telomere by doubling back upon itself, but it prevents elongation. 
Also present at the telomere are binding proteins, such as Cdc13p and Estlp, which, 
together, provide a sort of "docking site" (Lundblad, 1996) for telomerase. Other proteins, 
such as Rap Ip and Rifl p, are also involved in this, and regulate the access telomerase has to 
the end of the chromosome. Inactivation of the gene encoding for these causes a loss of the 
protective binding protein, and the telomerase has unrestricted access to the telomere (Schulz, 
1994 ), leading to maintenance oflength, or runaway elongation, in which the size of the DNA 
can increase by up to 100 times (McEachern, 1995). In addition, the Est 1 protein may act as a 
component oftelomerase, which directs recognition of the telomere by the enzyme. 
In conventional DNA replication, there is not always completion of chromosome ends, 
so with each progressive division, information is lost, and the chromosome gradually wears 
away. In the absence of telomeres, the DNA lost is actual encoded information, and mutations 
in the cell can occur. Telomerase is present in regenerative, fetal, and hematopoietic tissue, 
such as the crypts of the small intestine and in the bone marrow, where cells are continuously 
being made and sent into the periphery. The enzyme maintains telomere length by balancing 
telomere shortening with elongation, fluctuating slightly within the allowable range, near the 
average length. That is, there is a dynamic balance between lengthening and shortening, within 
which the net optimum length is maintained. In non-regenerative somatic (non-sex) tissue, 
with each progressive division, some of the length is lost, until the size of the segment reaches a 
crucial lower limit, upon which division ceases and the cell dies. As the telomere shrinks, it is 
thought that it keeps a "biochemical tally" (Lewis, 1996) of how many divisions have occurred. 
Interest in telomeres began nearly a century ago, when early geneticists noticed that 
chromosomes lacking tips would fuse together and then disappear during cell division. 
Leonard Hayflick reported in 1961 that a human cell in vitro can only replicate a certain 
number of times, about 40 to 60, after which the cell enters senescence. Exploration of this 
idea led to the realization that the ends of the chromosomes are the controlling factor of this. 
In 1972, James Watson described the "lagging strand problem", which was mentioned 
previously: how DNA can be lost due to the discontinuous replication occurring along the 
lagging strand. This is prevented by the telomeric overhang, which is lost instead of the 
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encoding DNA (Lewis, 1996). Little was known about how these chromatin segments were 
controlled until 1985, when an enzyme was found that was able to lengthen a G-rich strand of 
DNA on an existing chromosome without the presence of a DNA template. Carol Greider and 
Elizabeth Blackburn isolated telomerase from the pond ciliate, Tetrahymena thermophila. The 
chromosomes in sex cells of this organism shatter, then replicate, producing thousands of 
telomeres (Lewis, 1996). These were the first animals whose telomeric sequence was 
identified and it is very close to that of vertebrates, being only one base pair off in the sequence 
of six. The mechanism of elongation of these was probed, to eventually lead to the 
identification of a ribonucleic protein as the governing factor in telomeric replication. It 
lengthens the G-rich DNA strand, without using a DNA template. This enzyme was eventually 
named telomerase, and much has been discovered about it in the relatively few years since. 
One of the most interesting aspects of it is its ability to synthesize DNA without the 
presence of a DNA template, since it is a mix of RNA and protein. Because the removal of the 
RNA primer leaves an 8-12 base G-rich tail at its 5' end, this serves as a substrate for the 
production of more telomerase. As long as telomerase continues to synthesize more telomeric 
DNA than is lost each time the cell replicates, the telomere will lengthen. Through various 
factors, such as the efficiency of the telomerase, its level of activity at each telomere, and the 
rate of degradation, telomere length is either increased, decreased, or remains near a fixed 
average (Zalcian, 1995). 
Another aspect of telomere biology that is interesting is the way replication is 
controlled. In some organisms, such as Saccharomyces cerevisiae, or baker's yeast, telomere 
elongation is regulated by the cell cycle. For instance, the single-stranded G-rich tail is present 
in the late synthesis, or S phase, of mitosis, but disappears before the beginning of the next cell 
cycle. In mammals, telomerase activity is developmentally regulated. That is, it is present in 
immature cells, but not in healthy, adult, differentiated cells (Dionne, 1996). 
The genes encoding telomerase have been cloned from a variety of animals, including 
mice and humans. So far, five genes required for telomerase-mediated elongation of the 
telomere have been isolated (Lendway, 1996). If the cloned gene from a regenerative cell is 
introduced into a somatic cell, it can lead to uncontrolled cell growth: since the telomerase is 
always present, it can constantly work to add telomeric sequences to the chromosome and 
prevent the normal condition of cellular aging, which controls cell division and number in a 
given area. This uncontrolled cell growth can, of course, lead to cancer. This information 
guided scientists to search for the presence oftelomerase in cancerous tissue. 
The discovery of the activity of telomerase was initially made in ovarian carcinomas 
(Counter, 1994). Since then, telomerase has been isolated in more than 90% of human 
malignant tumors (Autexier), and it has been found that the telomeres in tumors are, on 
average, shorter than those in healthy somatic cells (Counter, 1994), and the length is also 
more constant. This implies that the telomerase, since it is present, can maintain a shorter net 
length of the telomere. It is not necessary that it originally produces a long strand of telomeric 
DNA, to be gradually worn away as the organism ages. Since the telomerase is always 
present, it can work ceaselessly to supply new telomeric sequences to the chromosome, as the 
originals are degraded. 
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Another fact worthy of note is that in the tumors analyzed, the presence of telomerase 
was only detected after the telomeres had become very short (Counter, 1994). This appears to 
indicate that the healthy cells age normally, and the telomeres shorten to a point, where there is 
a mutation in one of the genes encoding for telomerase. At this time, telomerase is reactivated 
in the cell, normal cellular senescence is halted, and uncontrolled cell proliferation ensues. 
Over the years, scientists have devised the telomere hypothesis: a model of the control 
and activity of the telomere and telomerase in marrunalian cells, and their interactions Autexier, 
1996). 
1.) T elomerase is present and active in gerrnline tissues where telomere length is maintained. 
This is where telomerase level is fairly steady, maintained by fluctuations around a mean length. 
2.) Telomerase is not present in normal somatic cells where telomere shortening occurs with 
each division, as a way of monitoring how many cell divisions have taken place. Shortening 
occurs steadily until the telomeres are so short that DNA damage would occur if they 
continued to divide, and the cell dies. 
3.) During the rest of the lifespan, telomeres continue to shorten and the cells enter a period of 
crisis, during which most cells die. In some, however, telomerase is reactivated and the cell line 
becomes immortal: the cells can replicate themselves indefinitely. 
4.) After crisis, these positively selected cells continue to demonstrate activated telomerase and 
telomere length is stabilized, and in some cases, the telomeres continue to elongate. 
(Chantal, 1996). 
It is because of this last information, that immortal and cancerous cells contain 
telomerase, that this has implications in research on cancer and other age-related diseases. The 
presence of telomerase activity in immortal cells indicates that telomerase inhibition could be a 
viable anti-cancer treatment, and that tests for the presence of the enzyme could be markers for 
the existence of tumors in a specific tissue. Also, abnormally short telomeres are present in 
cells located in the linings of blood vessels. This premature or accelerated aging in these tissues 
can raise the risk of stroke and heart attack (Lewis, 1996). 
A company was founded in 1992 specifically to use the ideas of cell senescence to treat 
and predict the risk of diseases of aging. Geren Corporation was one of the first to begin 
research on telomerase inhibitors, and has become a leading research center for telomerase 
inhibition. Since then many others have begun their own research, because telomere biology 
has become such an expanding and promising field. 
Possible uses of this knowledge of telomeres and telomerase are not only to predict the 
risk and onset of atherosclerosis, but low levels of telomerase have been observed in hepatic 
tissue, and most of the cirrhotic liver tissues taken from people who are, so far, cancer-free. 
And although these are interesting and important avenues to be explored, the search for a cure 
for cancer, is, of course, prominent. 
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A promising aspect of this technology is the fact that telomerase activity is increased in 
more severe forms or stages of certain cancers, such as breast cancer. A telomerase test may 
indicate how far a cancer has progressed, providing a clue as to the kind of treatment needed in 
a particular case, whether it be a lumpectomy or mastectomy and radiation (Lewis, 1996). 
When telomerase was initially isolated in human malignant cells, it seemed as though 
this could be a "miracle cure" and finally end the threat that cancer poses. Chemotherapeutic 
agents and radiation are so toxic to the body, that a simple, natural restoration of the normal 
progression of cell aging would be a welcome reprieve. In 1994, Calvin Harley, then the 
director of cell biology at Geren Corporation, had hoped to have the drugs in clinical trials by 
1996 (Borman, 1994). In just over a year, however, after research had been underway for just 
a short time, scientists realized that the rime frame would be longer than that. 
For one thing, the presence of telomerase in stem cells and regenerative tissue can pose 
a problem, since inhibiting telomerase in the body can damage these cells, preventing their 
differentiation and maturation. This might not be a major problem, since, as mentioned before, 
telomeres in tumor cells are usually shorter than in these stem cells, and telomere shortening 
would have a greater impact on the cancerous tissue rather than the developmentally immature 
but essential tissues (Lundblad, 1996). 
Although the presence of telomerase in more than 90% of human malignancies shows a 
strong correlation between cancer and the telomere, the fact that there is even 10% of tumors 
that lack the enzyme is an obstacle to this research. In the last couple of years, it has been 
found that cells that do not contain telomerase are still able to maintain telomere length and 
even elongate them (Dionne, 1996). 
T elomere length is measured by calculating the mean size of the terminal restriction 
fragments (TRF), which are comprised not only of the telomeres themselves, but of short 
sequences directly adjacent to them which are transcriptionally repressed, or not expressed 
(Autexier, 1996). As there are differences in telomere size among the tissue types, when 
comparing length, cancerous and healthy cells from the same tissue type must be used. In most 
tumors, the average telomere length is shorter even than that of senescent cells. But in some, 
telomerase has been activated to such an extent that the telomeres can be much longer than 
even those of young cells, demonstrating that deregulation of size has occurred. This is the 
result of the alteration, for one reason or another, of the genes encoding the enzyme, and could 
be the beginning stage of cancer. lf telomerase could be inhibited in these cells, reverting to the 
processes of healthy cells, this could be prevented. 
One drawback to this is the possibility that the telomeres begin short, and then as 
telomerase is re-activated, they lengthen when the process of senescence is reversed. A way to 
approach this is to use telomerase as a marker, and when it reappears to then treat the cancer 
using a different method. 
The problem with relying on this assumption is that not all tumors are telomerase-
positive. Many have cells where the telomere is more than twice as long as it is even in young, 
healthy cells, and telomerase is not present. A certain type of brain tumor, anaplastic 
astrocytoma, is almost always telomerase-negative, although it might conceivably originate 
from a positive tumor. This, and other evidence that telomeres can replicate without the 
activity of telomerase has led scientists to realize that there is an alternative pathway for cell 
proliferation (Langford, 1995). 
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Although this is not necessarily the case in a majority of situations, it is still a possibility 
in a small percentage of cancers. If telomerase were inhibited in a tumor, the tissue could then 
change the way it grows and find another way to do so. This could then select for telomerase-
independent cancers and lead to a greater occurrence of these. The way to approach this is to 
delineate the pathway by which these other cell lines proliferate, find a way to inhibit that, then 
use both methods in conjunction (Autexier, 1996, and Lewis, 1996). This is similar to the 
method used to treat some bacterial and viral infections, so as not to select for resistant strains. 
By blocking all possible pathways of growth and replication, we essentially build a fence 
around the tissue or infected cell, and stop it right where it is. That is not to say the cells will 
not be able to find another way, but if that were to occur, we could then block that, too. 
The alternative mechanism has begun to be investigated, and it appears that some cells 
use recombination to extend the telomeres (Zakian, 1995), although there are many questions 
still to be answered in this area. 
Due to these other possibilities, the telomere hypothesis must be refined. The 
information stated in it is still true, but there is now more. T elomerase is still strongly linked 
with cancer development, but there are other causes as well, and these must be taken into 
consideration when deciding how to proceed in each situation. 
Inhibition could still be used, perhaps, but the tissue must be monitored for the 
possibility that it has found a way around the treatment. Also, the healthy germ cells and those 
lining the blood vessels need to be watched so that they do not shorten prematurely to a length 
that decreases their viability. And telomerase has been detected in low levels in mature B and 
T cells, not enough to lengthen the telomere, but the very presence reminds us of the possible 
side effects of inhibiting the enzyme (Lewis, 1996). The treatment of one disease can, 
obviously, not induce the beginning of another. 
Some tend to view the discovery of alternative pathways as a setback. But telomere 
research has progressed so rapidly in just the last several years that the overall atmosphere must 
be that of hope. In a 1983 interview, James Watson said "None of this could have been 
predicted. Now it 's hard to imagine things going any faster. But it will be faster. Mysteries 
wi!J tumble. All is now open to experimental attack and problems we can't even foresee today 
will be identified and solved within less than a decade" (Garrett, 1996). Cloning of other genes 
that regulate the repression or expression of binding proteins or enzymes will help to clear the 
way, and the marking then blocking of the new pathways will help us to go even further. There 
are obstacles, but within a few more years, the possibility of fighting many of the geriatric 
diseases we face today could be very close. 
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